|
|
|
|
|
|
Sponsors and Collaborators: |
ERYtech Pharma Centre Leon Berard |
Information provided by: | ERYtech Pharma |
ClinicalTrials.gov Identifier: | NCT00723346 |
Primary objective :
Secondary objective :
Condition | Intervention | Phase |
Acute Lymphoblastic Leukemia |
Biological: GRASPA Drug: native L asparaginase |
Phase I Phase II |
MedlinePlus related topics: | Leukemia, Adult Acute Leukemia, Adult Chronic Leukemia, Childhood |
Drug Information available for: | L-Asparaginase |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Pharmacokinetics/Dynamics Study |
Official Title: | Administration of Allogenic of Red Blood Cells Loaded L Asparaginase in Acute Lymphoblastic Leukemia Relapse. |
Enrollment: | 25 |
Study Start Date: | January 2006 |
Estimated Primary Completion Date: | August 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
1: Experimental |
Biological: GRASPA
50 UI/Kg
|
2: Experimental |
Biological: GRASPA
100 UI/Kg
|
3: Experimental |
Biological: GRASPA
150 UI/Kg
|
4: Active Comparator |
Drug: native L asparaginase
10000UI/m2, 14 infusions during 4 chemotherapy cycle
|
Ages Eligible for Study: | 1 Year to 55 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Responsible Party: | ERYtech Pharma ( Yann Godfrin / Chief Executive Officer ) |
Study ID Numbers: | GRASPALL 2005-01 |
First Received: | July 24, 2008 |
Last Updated: | July 25, 2008 |
ClinicalTrials.gov Identifier: | NCT00723346 |
Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|